Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific Inc. (NYSE: TMO) files a wide range of documents with the U.S. Securities and Exchange Commission, and this page aggregates those SEC filings for investors tracking TMO. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, and its filings describe the terms, rankings and covenants of these securities, as well as material events affecting the business.
Recent Form 8‑K filings illustrate the types of information Thermo Fisher discloses. Several 8‑Ks detail public offerings of senior notes in U.S. dollars and euros, including maturities, interest payment schedules, redemption provisions, change‑of‑control protections and the use of proceeds for general corporate purposes such as acquisitions, debt repayment or refinancing, working capital, capital expenditures or equity repurchases. Other 8‑Ks report the completion of the acquisition of Solventum Corporation’s purification and filtration business and the signing of a definitive agreement to acquire Clario Holdings, Inc.
Thermo Fisher also uses 8‑K filings to communicate quarterly financial results, leadership transitions and organizational changes. For example, filings describe announcements of financial results for specific fiscal quarters, the planned retirement of the Senior Vice President and Chief Financial Officer and the appointment of a successor, and updates to the organizational structure and leadership team, including changes in executive roles.
On Stock Titan’s SEC filings page for TMO, users can access these current reports alongside other registered securities information, and benefit from AI‑powered summaries that explain key terms, highlight significant covenants, and clarify how new debt offerings, acquisitions, leadership changes or other material events may affect Thermo Fisher Scientific’s capital structure and corporate profile.
Thermo Fisher Scientific director reports additional deferred stock units. A Thermo Fisher Scientific Inc. (TMO) director filed a Form 4 for a transaction dated 12/31/2025. The filing shows an acquisition of 53.93 phantom stock units, each convertible into one share of common stock, recorded in Table II as a derivative security held directly.
The 53.93 units were credited at a price of $579.45 per unit under the company’s Deferred Compensation Plan for Directors. Under this plan, quarterly director retainers are deferred into common stock units based on the closing stock price at quarter end. The underlying shares are scheduled to be distributed in stock when the director’s service ends for any reason or upon a change of control.
Thermo Fisher Scientific director reports deferred stock units grant
A Thermo Fisher Scientific Inc. director, R. Alexandra Keith, reported an acquisition of 53.93 phantom stock units on December 31, 2025 under the company’s Deferred Compensation Plan for Directors. These units are credited based on the closing stock price at quarter end, which was $579.45 per unit, and each unit is convertible into one share of common stock. Following this transaction, the director beneficially owns 1,204.42 phantom stock units, which will be distributed in stock after the director’s service ends or if there is a change of control.
Thermo Fisher Scientific director reports deferred stock units under incentive plan. A reporting person serving as a director of Thermo Fisher Scientific Inc. (TMO) disclosed a routine change in holdings through a Form 4 filing. On December 31, 2025, the director received 73.35 phantom stock units, each convertible into one share of common stock, under the company’s Deferred Compensation Plan for Directors.
The units were credited at a price of $579.45 per unit, based on the closing stock price at quarter end, bringing the director’s total derivative holdings to 17,502.02 stock units held directly. These stock units are designed to mirror common stock and are distributable in shares when the director’s service ends or upon a change of control, aligning director compensation with long‑term shareholder value.
Thermo Fisher Scientific director reports deferred stock unit grant
A Thermo Fisher Scientific Inc. (TMO) director reported receiving 64.72 phantom stock units on December 31, 2025 under the company’s Deferred Compensation Plan for Directors. These units are convertible into common stock on a 1-for-1 basis and were credited at a price of $579.45 per unit, based on the closing stock price at quarter end. Following this transaction, the director beneficially owns 2,638.67 derivative securities, held directly. Under the plan, directors’ retainers are deferred quarterly into common stock units, which are distributable as stock when director service ends for any reason or upon a change of control.
Thermo Fisher Scientific Inc. director transaction: Director Jennifer M. Johnson reported acquiring 53.93 phantom stock units tied to Thermo Fisher common stock on December 31, 2025. The units were credited at a price of $579.45 per unit under the company’s Deferred Compensation Plan for Directors.
Each phantom stock unit is convertible into one share of common stock and is distributable as stock after the director’s service ends or upon a change of control. Following this transaction, Johnson directly holds 595.29 phantom stock units. She is also President and Chief Executive Officer of Franklin Resources, Inc. and disclaims beneficial ownership of Thermo Fisher shares held in Franklin Templeton-managed client accounts.
Thermo Fisher Scientific director reports stock gift
Scott M. Sperling, a director of Thermo Fisher Scientific Inc., reported a transaction in the company’s common stock on December 10, 2025. The filing shows he disposed of 4,386 shares of common stock in a transaction coded "G," indicating a gift, at a reported price of $0 per share. Following this transaction, he beneficially owns 68,980 shares of Thermo Fisher Scientific common stock in direct ownership.
Thermo Fisher Scientific executive Michel Lagarde reported option exercises and a stock sale. On December 4, 2025, he exercised stock options for 18,637 shares of common stock at an exercise price of $105.17 per share and another 22,046 shares at an exercise price of $132.66 per share. On the same day, he sold 22,046 shares of Thermo Fisher Scientific common stock at a weighted average price of $563.56 per share, with individual sale prices ranging from $563.38 to $564.20.
After these transactions, Lagarde beneficially owned 84,116.909 shares of Thermo Fisher Scientific common stock in direct form. The options exercised had previously vested in scheduled installments in 2017, 2018, 2019 and 2020, and following the reported exercises, the specific option grants referenced now show 0 derivative securities remaining.
Thermo Fisher Scientific Inc. executive Michel Lagarde reported multiple stock option exercises and related stock sales. As Executive Vice President & COO, he filed a Form 4 for transactions dated December 2 and 3, 2025.
On December 2, Lagarde exercised options to acquire 36,000 shares of common stock at an exercise price of $105.17 per share, then sold 30,000 shares at a weighted average price of $581.92. On December 3, he exercised options for another 68,000 shares at $105.17, and sold 29,479 shares at a weighted average price of $583.33 plus 2,521 shares at a weighted average price of $584.11.
After these transactions, Lagarde directly held 65,479.909 shares of Thermo Fisher common stock and 18,637 stock options with a $105.17 exercise price expiring on July 20, 2026, which had vested in two equal installments on August 29, 2017 and 2020.
Thermo Fisher Scientific insider Michel Lagarde has filed a Form 144 indicating his intent to sell company stock. The notice covers 22,046 shares of common stock to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 12424320.59. The filing notes that 375708059 shares of common stock were outstanding.
Lagarde has also sold Thermo Fisher common shares in recent months. The notice lists sales of 4638 shares on 11/13/2025 for gross proceeds of 2756934.80, 30000 shares on 12/02/2025 for 17457612.00, and 32000 shares on 12/03/2025 for 18668515.20. By signing the notice, the seller represents that he is not aware of any material adverse, nonpublic information about the company’s current or prospective operations.